XVIR-TAT

**XVIR-TAT** is a preclinical gene editing program developed by Exavir Therapeutics for a potential functional cure of HIV infection. It utilizes CRISPR-Cas9 delivered via lipid nanoparticles (LNPs) encoding Cas9 nuclease and proprietary Tat-targeted guide RNAs (gRNAs) to excise HIV proviral DNA, specifically targeting the HIV *tat* gene. Preclinical data published in *EBioMedicine* (2021) demonstrated up to 100% HIV suppression and complete elimination of HIV from infected human cells in vitro, with no detectable off-target edits, supporting its potential as an antiretroviral therapy for HIV eradication.[2][8]